VXRT Vaxart

Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine

Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
EN
13/10/2020

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Upcoming Conference Calls

Vaxart to Host Upcoming Conference Calls Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today announced it will host two upcoming webcast conference calls. Third Quarter 2025 Financial ResultsVaxart will provide a business update and report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 13, 2025. The Vaxart senior mana...

November 7, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Va...

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025 SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research featuring its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 taking place October 19-22, 2025, at the Georgia World Congress Center in Atlanta. IDWeek Oral Abstract Presentation: Presen...

October 20, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candid...

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025. Vaxart’s mission is to ...

October 8, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

Vaxart Announces Withdrawal of Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has withdrawn its reverse stock split proposal. “After careful consideration, we have decided to officially withdraw our reverse stock split proposal. Moving forward, we will continue to communicate frequently with our stockholders across multiple channels...

September 19, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Appoints W. Mark Watson as Lead Independent Director

Vaxart Appoints W. Mark Watson as Lead Independent Director In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted FOR the reverse stock split, to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platf...

September 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch